A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma

International Immunology

Volumn 28, Issue 2, 2016, Pages 87-97

  Stanojevic, Ivan ^a   Miller, Karolina ^b   Kandolf Sekulovic, Lidija ^a   Mijuskovic, Zeljko ^a   Zolotarevski, Lidija ^a   Jovic, Milena ^a   Gacevic, Milomir ^a   Djukic, Mirjana ^c   Arsenijevic, Nebojsa ^d   Vojvodic, Danilo ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b DORSET COUNTY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CLINICAL CENTER KRAGUJEVAC   (Serbia)

Author keywords

Immunophenotype; Mdsc; Progression; Subset

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HLA DR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER STAGING; CELL LINEAGE; CELL MATURATION; CELL SUBPOPULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DENSITY GRADIENT; DISTANT METASTASIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUTROPHIL LYMPHOCYTE RATIO; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SUPPRESSOR CELL; CARCINOGENESIS; CELL DIFFERENTIATION; DISEASE FREE SURVIVAL; FOLLOW UP; GRANULOCYTE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MELANOMA; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SKIN TUMOR;

CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINEAGE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GRANULOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; MELANOMA; MYELOID CELLS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SKIN NEOPLASMS;

EID: 84961800760     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv053     Document Type: Article

References (53)

1. Young, M. R., Newby, M. and Wepsic, H. T. 1987. Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47:100.
2. Bronte, V., Wang, M., Overwijk, W. W. et al. 1998. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161:5313.
3. Nagaraj, S. and Gabrilovich, D. I. 2010. Myeloid-derived suppressor cells in human cancer. Cancer J. 16:348.
4. Gabrilovich, I. D., Ostrand-Rosenberg, S. and Bronte, V. 2012. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:253.
5. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S. and Bronte V. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238.
6. Kimberly, R. J., Rodabe, N. A., Oscar, R. et al. 2013. Myeloidderived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol. Immunother. 62:1711.
7. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Meyer, E., Cole, D. J. and Montero A. J. 2009. Increased circulating myeloid- derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:49.
8. Meyer, C., Cagnon, L., Costa-Nunes, C. M. et al. 2014. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63:247.
9. Filipazzi, P., Valenti, R., Huber, V. et al. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colonystimulation factor-based antitumor vaccine. J Clin. Oncol. 25:2546.
10. Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V. and Kiessling, R. 2010. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-Sign. Cancer Res.70:4335.
11. Montero, J. A., Diaz-Montero, M. C., Kyriakopoulos, E. C., Bronte, V. and Mandruzzato, S. 2012. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother. 35:107.
12. Schilling, B., Sucker, A., Griewank, K. et al. 2013. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int. J. Cancer 133:1653.
13. Mandruzzato, S., Solito, S., Falisi, E. et al. 2009. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:6562.
14. Gabrilovich, I. D. 2011. Myeloid-derived suppressor cells and tumor escape. AACR 102nd Annual Meeting, April 2-6, p. 100. Orlando, FL.
15. Talmadge, E. J. and Gabrilovich, I. D. 2013. History of myeloidderived suppressor cells. Nat. Rev. Cancer 13:739.
16. Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E. and Rosenberg, S. A. 2012. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin. Cancer Res. 18:5212.
17. Khaled, Y. S., Ammori, B. J. and Elkord E. 2014. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. J. Immunol. Res. 2014:879897.
18. Youn, J. I., Nagaraj, S., Collazo, M. and Gabrilovich, D. I. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791.
19. Ribechini, E., Greifenberg, V., Sandwick, S. and Lutz, M. B. 2010. Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol. 199:273.
20. Zhi, L., Toh, B. and Abastado, J. P. 2012. Myeloid derived suppressor cells: subsets, expansion and role in cancer progression. In Biswas, S., ed., Tumor Microenvironment and Myelomonocytic Cells, p. 63. Rijeka, Croatia.
21. Dumitru, A. C., Moses, K., Trellakis, S., Lang, S. and Brandau, S. 2012. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61:1155.
22. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. and Bronte, V. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222:162.
23. Manjili, H. M. 2012. Phenotypic plasticity of MDSC in cancers. Immunol. Invest. 41:711.
24. Stockmann, C., Schadendorf, D., Klose, R. and Helfrich, I. 2014. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front. Oncol. 4:69.
25. Yang, W. C., Ma, G., Chen, S. H. and Pan, P. Y. 2013. Polarization and reprogramming of myeloid-derived suppressor cells. J. Mol. Cell Biol. 5:207.
26. Najjar, Y. G. and Finke, J. H. 2013. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol. 3:49.
27. Gabrilovich, D. I. and Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162.
28. Dilek, N., Vuillefroy de Silly, R., Blancho. G. and Vanhove, B. 2012. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front. Immunol. 3:208.
29. Yu, J., Du, W., Yan, F. et al. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190:3783.
30. Nagaraj, S. and Gabrilovich, D. I. 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68:2561.
31. Raber, P., Wyczechowska, D. and Rodriguez, P. 2012. Granulocytic and monocytic populations of tumor-infiltrating myeloid-derived suppressor cells (MDSC) suppress T cell proliferation through independent mechanisms. J. Immunol. 188:74.7.
32. Heuvers, M. E., Muskens, F., Bezemer, K. et al. 2013. Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. Lung Cancer 81:468.
33. Raber, P., Ochoa, A. C. and Rodríguez, P. C. 2012. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol. Invest. 41:614.
34. Movahedi, K., Guilliams, M., Van den Bossche, J. et al. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233.
35. Wesolowski, R., Markowitz, J. and Carson, W. E. III. 2013. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J. Immunother. Cancer 1:10.
36. Schmielau, J. and Finn, O. J. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61:4756.
37. Elghetany, M. T. 2002. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol. Dis. 28:260.
38. Brandau, S., Trellakis, S., Bruderek, K. et al. 2011. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89:311.
39. Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. and Gabrilovich, D. I. 2012. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91:167.
40. Greifenberg, V., Ribechini, E., Rössner, S. and Lutz, M. B. 2009. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development. Eur. J. Immunol. 39:2865
41. Shipp, M. A., Stefano, G. B., Switzer, S. N., Griffin, J. D. and Reinherz, E. L. 1991. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide- induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood l78:1834.
42. Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R. and Ochoa A. C. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:1553.
43. Sagiv, J. Y., Michaeli, J., Assi, S. et al. 2015. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep. 10:562.
44. Pillay, J., Tak, T., Kamp, V. M. and Koenderman, L. 2013. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and difference. Cell. Mol. Life Sci. 70:3813.
45. Raychaudhuri, B., Rayman, P., Ireland, J. et al. 2011. Myeloidderived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro. Oncol. 13:591.
46. Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A. and Middleton, G. W. 2011. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are associated with significant Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60:1419.
47. Sevko, A. and Umansky, V. 2013. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J. Cancer 4:3.
48. Wilcox, R. A., Nevala, W. K., Thompson, M. A., Witzig, T. E., Ansell, S. M. and Markovic, S. N. 2009. CD14+hla-DR-/lo myeloid-derived suppressor cells express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma. Blood 114 (ASH Annual Meeting Abstracts, New Orleans, LA): Abstract 464.
49. Vuk-Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X. and Dietz, A. B. 2010. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70:443.
50. Ilkovitch, D. and Lopez, D. M. 2008. Immune modulation by melanoma- derived factors. Exp. Dermatol. 17:977.
51. Pflugfelder, A., Kochs, C., Blum, A. et al. 2013. Malignant melanoma S3-guideline "Diagnosis, therapy and follow-up of melanoma." Journal der Deutschen Dermatologischen Gesellschaft 11(Suppl. 6):1.
52. Filipazzi, P., Huber, V. and Rivoltini, L. 2012. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61:255.
53. Kotsakis, A., Harasymczuk, M., Schilling, B., Georgoulias, V., Argiris, A. and Whiteside, T. L. 2012. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol. Methods 381:14.